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Abstract
Proteotoxicity caused by an imbalanced protein quality control surveillance system is believed to
contribute to the phenotypes associated with aging as well as many neurodegenerative diseases.
Understanding and monitoring the impact of proteotoxicity in these processes offers researchers
keen insight into the biology of aging, as well as other conditions that share similar pathological
etiologies. In this methods review we present various technical approaches that can be used to
calculate and characterize the phenotypes associated with aging that are linked to increased
proteotoxicity. Methods such as the measurement of oligomer protein expression and the capacity
of proteasome function are useful tools in observing both aging phenotypes and neurodegenerative
diseases, both of which share the phenomenon of impaired protein homeostasis.
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1. Introduction
Proteotoxicity caused by misfolded and aggregated proteins is considered to be an
underlying mechanism mediating the pathogenesis of late onset neurodegenerative diseases
such as Alzheimer's diseases (AD), Parkinson's diseases (PD) and polyglutamine diseases
[1,2]. These diseases are characterized by the expression of specific disease-associated
proteins (such as Aβ, α-synuclein, tau, and huntingtin) which result in the formation of
misfolded toxic proteins and protein aggregates [1]. This, in conjunction with the
impairment of a protein degradation system that normally removes toxic nonfunctional
proteins and organelles, greatly contribute to the exacerbation of these diseases [3,4].
Similar findings of accumulated damaged and misfolded proteins and inefficient protein
degradation are also prevalent in the aging process.
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The aging process is a highly complex progression consisting of both physiological and
pathological steps involving the functional decline of most biological systems including
DNA repair, telomere maintenance and protein turnover system [5,6]. Similar to the findings
associated with neurodegenerative diseases, studies now support the theory that cellular
malfunction caused by accumulation of damaged and misfolded proteins and impaired
protein degradation is a major contributing factor in the aging process [7,8].
Considering the impact that suboptimal maintenance of protein homeostasis has on aging
and neurodegenerative diseases, monitoring proteotoxicity in conjunction with the analysis
of pathological phenotypes is a valuable approach for evaluating the progress of
neurodegenerative disease as well as aging processes. Previously we reported on the
importance of properly maintained protein homeostasis in aging using the CHIP deficient
mouse model. CHIP (carboxyl terminus of Hsp70-interacting protein) is a ubiquitin ligase
and molecular chaperone essential for many protein quality control processes within the cell
[9-11]. Mice deficient in CHIP exhibit a shortened life span with a premature aging
phenotype accompanied by a decline in protein quality control [12]. In this Methods review,
we discuss the techniques used in our study to characterize accelerated aging and to monitor
protein toxicity in our studies. Given the similarities in the pathologies associated with aging
and neurodegenerative diseases, the techniques outlined in this review should be useful to
researchers wishing to measure the progression and mechanics of both aging and other
diseases associated with protein aggregates and decreased protein quality control. Most of
data present here is adapted from our previously published report using the CHIP deficient
mouse model [12].
2. Methods
Tissue samples used in all of the following methods are collected from mice of various ages
(3, 6, 12, and 24 month old) in order to gain insight into the pathological and biochemical
changes of various parameters over the course of normal and accelerated aging. Mice are
euthanized with a CO2 overdose followed by cervical dislocation and various tissues are
extracted, weighed and prepared for storage by snap freezing in liquid nitrogen within 20
min following euthanasia. Tissue samples are stored at -80°C until needed. For statistical
analysis, at least 3 mice per group (typically 5 animals per group) are used in each
experiment.
2-1. Analyzing age-associated phenotypes in mouse models: anatomical and biochemical
characteristics of aging
Studies of premature/accelerated aging in mammals commonly use anatomical and
biochemical changes as an indicator of age-associated pathophysiological phenotypes [6,13].
In addition, a decrease in maximal lifespan without specific pathological features is another
representative characteristic of an accelerated aging phenotype in mouse model systems
[14]. Here we summarize the general methods used to identify age-associated
phathophysiological changes in mouse models.
2-1-1. Longevity analysis: Kaplan-Meier survival curve—Median survival and
maximum survival is a general but extremely useful determinant of changes in longevity.
Although mice exhibit minor variations in longevity depending on genetic strain and gender,
the average laboratory mouse can live up to 2-3 years when housed in a specific pathogen
free (SPF) environment [15]. In the case of mortality related purely to normal aging, death is
preceded by a generalized lack of movement and response to stimuli and difficulty of
breathing, in the absence of any outward sign of diseases. Using GraphPad Prizm software, a
Kaplan-Meier curve, which estimates survival fraction over time, is plotted and a logrank
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test is performed to determine the significant difference in survival between the various
groups tested. Figure 1 shows an example of the Kaplan-Meier survival curve obtained for
24 CHIP +/+ and 27 CHIP-/- female mice that were observed for more than 2 years in our
laboratory. The result of the logrank test indicates that the survival of the two genetic groups
is significantly different (p=0.0003).
2-1-2. Body composition analysis—Changes in body composition is a useful index for
determining the progression of both aging and disease as it offers a more detailed insight
into these processes than just changes in body weight alone. Body composition analysis
includes monitoring the degree of body fat, lean tissue and bone density. Age is associated
with a major change in body composition in the form of declined lean body mass [16-18].
Bone loss (measured by a decrease in bone density) is another indicator of the aging process
and correlates with the progression of osteoporosis in human aging [19]. Body composition
is measured by dual energy X-ray absorptiometry (DEXA) using a Lunar PIXImus
densitometer (GE-Lunar Corp; Nagy, 2000 #150}. For this analysis, mice are anesthetized
with pentobarbital (60 mg/kg) and subjected to scanning on a Lunar PIXImus densitometer.
Data obtained from the PIXImus densitometer includes measurements of bone mineral
content (BMC, g), bone mineral density (BMD, g/cm2), % fat and % lean for individual
animals. Another age-associated skeleton malformation is the progress of kyphosis, a lateral
curvature of the spine [20]. Although severe hyperkyphosis can be observed without
measurement, detailed degrees of thoracic kyphosis can be monitored using a radiographic
Cobb's angle. The angle is calculated by drawing two lines in the thoracic curve at spinal
levels T4 and T12. The resultant the angel between the intersecting perpendicular lines is
defined as the Cobb's angle. A higher degree of Cobb's angle indicates a more severe form
of kyphosis.
2-1-3. Evaluating skin atrophy—Skin consists of three layers, namely the epidermis,
dermis and subcutaneous layers. The major age-associated phenotypes in skin are
characterized by atrophic skin and poor wound healing. Although both the epidermis and
dermis layers are known to become thinner with age, a reduced dermis layer is commonly
used to monitor skin atrophy since the dermis is much thicker and therefore easier to analyze
when it come to visualizing changes over time [21,22]. To calculate the thickness of the
dermis layer of skin, a section of skin from the back of the mouse is removed and embedded
in OCT compound and prepared for frozen histological analysis. Skin sections are stained
for Hematoxlyin and eosin to visualize the various skin layers and micrographs collected for
comparative analysis. The thicknesses of the dermis layer is measured in more than 10
different areas from one section to minimize inaccuracies due to local variations in layer
thickness. At least 3 different mice per group are used for statistical analysis. Figure 2A
illustrates an example image of skin sections taken from CHIP+/+ and CHIP-/- mice at 12
months of age. Histological skin sections of CHIP-/- mice exhibit a greater degree of dermal
thinning compared to CHIP+/+ mice, indicating advanced skin atrophic features in CHIP-/-
mice.
2-1-4 Cell proliferation assay: 3T9 protocol—Senescence refers to the distinctive and
irreversible G1 growth arrest condition caused by diverse stressors such as DNA damage
dysfunction in telomeres [23]. Cells undergoing senescence accumulate with age (owing to
the age-related decline in renewability of cells;[24]) and these senescent cells are believed to
contribute to the aging process. The most common way to monitor cellular senescence is to
measure the ability of cell division during cellular passages in non-immortalized primary
cells such primary mouse embryo fibroblasts (MEFs). After multiple passages, primary cells
undergo senesensce and stop dividing. In addition, they undergo a change in morphology
and physiological characteristics. Primary MEFs generated from mouse embryos at
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embryonic day 13.5 according to standard protocols are used to measure proliferation assay
using a 3T3 or 3T9 assay [25]. The 3T9 protocol is performed by plating cells at a density of
9×105 cells in 60-mm dishes. Cells are then replated after cell counts every third day (next
passage) to maintain the same cell density. Population doublings (PDs) are determined by
the following formula: log2 (number of cells harvested/number of cells seeded). PDs per
passage can be plotted to compare the ability of cell proliferation in different passages and
groups.
2-1-5. Senescence-associated β-galactosidase (SA-β-gal) activity assay in
primary MEFs—Another way to measure senescence in cells is to monitor galactosidase
activity in higher pH (pH 6). Lysosomal galactosidase activity is normally expressed in most
cells and is usually optimally detected in an acidic environment (pH 4). However, in
senescent cells and aging tissues (but not in quiescent and terminally differentiated cells)
galactosidase activity can be histochemically detected at a more basic pH (pH 6;[26]). It is
believed that an increase in lysosome number and activity during replicative senescence and
organismal aging is the cause for galactosidase activity being able to be detected at a more
basic pH [27] [28]. Galactosidase activity at pH 6, so called senescence-associated β-
galactosidase (SA-β-gal) activity, is considered a biochemical indicator of the senescence
process. SA-β-gal assays can be performed in vitro using primary MEFs at different
passages as well as in vivo using tissues from mice of different ages. SA-β-gal activity in
MEFs is measured by X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) staining
using a commercially available Senescence detection kit (BioVision). MEFs are grown in 12
or 24 well plates at different passages, washed with 1×PBS and fixed with 10%
formaldehyde for 10 min at room temperature. Following washing, cells that are to be
assayed for SA-β-gal activity are stained with the x-gal substrate solution overnight at 37°C.
The following day, cells are washed with 1×PBS and photographed under light microscopy
to reveal SA-β-gal staining. Quantification of X-gal positive cells is achieved by counting
positive cells in 20 different fields at 400× magnification. SA-β-gal activity can also be
measured in isolated tissue samples using the lableling procedure described above adapted
for frozen section histochemistry, however it should be noted that some tissues (such as liver
and spleen) can exhibit a high degree of background staining and this should be considered
carefully to ensure accurate data interpretation [29]. For whole animal studies, kidney is a
good tissue of choice in which to examine SA-β-gal activity. Figure 2B shows an example
of SA-β-gal staining in CHIP-/- and CHIP+/+ MEFs at passage 8, which corresponds to a
relatively late passage in primary MEFs and is therefore a good representation of aged cells.
Representative pictures indicate a higher number of X-gal positive cells in CHIP-/-MEFs
compared to CHIP+/+ MEFs at the same passages indicating cells from CHIP-/- mice
senesence faster compared to cells from CHIP+/+ mice.
2-1-6. Measuring oxidative damage—Oxidative stress in conjunction with
mitochondrial dysfunction has been linked to neurodegenerative diseases [30,31]. Oxidative
stress induces cellular toxicity by free radical/reactive oxygen species, resulting in damage
to cellular macromolecules including lipid, DNA and proteins. Increased oxidative stress
and damaged biomolecules are also a hallmark of the aging phenotype [32,33]. There are
several ways to detect the level of oxidative stress in cells and tissues including the
measurement of oxidized protein levels, cellular redox potential and lipid oxidation. The
presence and level of oxidized proteins (detection of protein carbonyl groups) can be
measured by the Oxyblot system (Millipore). This simple immonoblotting-based system
allows for the detection of carbonylated proteins in cells as well as tissue lysates by a
reaction with 2,4-dinitrophenyl (DNP) hydrazine using an anti-DNP polyclonal antibody.
Another way of monitoring the oxidative damage in a system is by measuring cellular redox
potential. Cellular redox potential decreases with age and certain disease states due to an
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increase in reactive oxygen species and can be monitored by balance between the reduced
(GSH) and the oxidized (glutathione disulfide, GSSG) forms of glutathione. A decrease in
GSH levels as well as an increase in the ratio of GSSG to GSH represent a lower redox
potential and also indicate higher oxidative stress. The ratio of GSSG to GSH can be
measured using a commercially GSH assay kit available from Cayman Chemical. Elevated
levels of lipid oxidation is another marker for increased oxidative stress during aging. 8-
isoprostane is a specific and abundant by-product of lipid peroxidation found in tissues and
circulating plasma. Measuring the level of 8-isoprostane is a reliable way to detect lipid
oxidation and therefore oxidative stress[34,35] and can be performed using a commercially
available 8-isoprostane enzyme immunoassay kit (Cayman Chemical).
2-2. Monitoring changes in protein homeostasis in vivo
As mentioned previously, changes in protein homeostasis are common in normal aging,
accelerated aging and in certain neurodegenerative diseases. Therefore, being able to
monitor and compare this parameter in various experimental settings is advantageous in
gaining insight into the progression of aging and disease states. Defects in the process and
components of protein quality control systems, such as molecular chaperones and the protein
degradation systems, increase with age and usually correlate with an increase in the
deposition of damaged proteins and protein aggregates. These altered protein species are
often times toxic to a cell, resulting in collapse of protein homeostasis with age and in
disease states [36]. Therefore, evaluation of protein homeostasis within a system can be
achieved by measuring both the accumulation of protein oligomers as well as the degree of
proteasomal activity in a given cell or tissue. To monitor changes in protein homeostasis
with age in our studies, we used two simple methods to measure the level of toxic oligomer
proteins and proteasome activity from tissue lysates.
2-2-1. Detection of soluble oligomer proteins in tissue lysates using a
commercially available anti-oligomer antibody—Soluble oligomer proteins are
intermediate products of fibril-type aggregates. Despite the fact that they are soluble in
nature, these oligomer proteins are known to cause higher cellular toxicity than larger fibril
aggregates [37,38]. The toxicity of soluble oligomer proteins is particularly well recognized
in Alzheimer's diseases associated with soluble Aβ peptides [39]. To measure the level of
soluble oligomer proteins without sequence specificity, a specific antibody (A11, Biosource)
has been developed which recognizes a common conformation-dependent structure present
in all soluble oligomers [39]. Originally, this anti-oligomer anibody was only used to detect
soluble Aβ oligomer proteins in AD samples, however the fact that this antibody probably
recognizes a oligomeric conformation common to many different proteins (in addition to Aβ
and small heat shock proteins), makes it difficult to interpret exactly which protein(s) are
actually being detected in an experiment. Nevertheless, the A11 antibody is now widely
utilized to determine general soluble oligomer proteins including Aβ oligomers, mutant α-B-
crystallin in desmin-related cardiomyopathy models, and soluble polyQ proteins in cell
culture system [40].
2-2-1-1 Preparation of soluble proteins from tissues: The detection of soluble oligomer
proteins has been successfully achieved in cells as well as certain tissues including the brain
and heart [39,41]. To extract soluble proteins from tissues, approximately 50mg to 100mg of
the desired tissue is collected and lysed in 200ul to 400ul of 1×PBS containing a protease
inhibitor (Roche) using pestle homogenizer. After removal of the insoluble proteins by
centrifugation (15000g, 15min, 4°C), the concentration of soluble protein is measured using
a Pierce® BCA Protein Assay Kit (Thermo Scientific). To avoid artificial protein aggregates
and denaturation, all materials are kept on ice and the generation of heat and bubbles is
minimized during tissue lysis.
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2-2-1-2 Dot blot analysis to detect oligomer proteins: To detect the expression of soluble
oligomer proteins, 10 to 20ug of soluble protein is loaded onto a nitrocellulose membrane
(0.4μm pore size) and then dried for several hours to overnight at room temperature.
Nonspecific labeling is blocked by incubating membranes with 5% (w/v) nonfat dry milk in
TBS containing 0.025% Tween 20 (TBST) overnight at 4°C. The A11 anti-oligomer
antibody (Biosource) is diluted in 3% (w/v) nonfat dry milk-TBST to a concentration of
1ug/ml and the membrane with bound soluble oligomer proteins is incubated for 2 hours at
room temperature or overnight at 4°C. The membrane is subsequently incubated with a
secondary antibody (HRP conjugated goat anti-rabit IgG, 1:5000 dilution) in 3% (w/v)
nonfat dry milk -TBST for 1 hour at room temperature. Between incubations, membranes
are washed 3 times with TBST. Following the last wash, the membrane is exposed to x-ray
film and developed using an Amersham ECL Plus™ Western Blotting Detection Reagents
(GE Healthcare). A positive control of purified α-B-crystallin (R120G) recombinant protein,
known for its ability to form soluble oligomers, is used for this assay [40]. In order to ensure
loading accuracy, soluble proteins are denatured by adding SDS (to a final concentration of
1%) and heated at 95°C for 5 min. Denatured proteins are then loaded onto a nitrocellulose
membrane, incubated with an anti-α-actin antibody and processed using the same procedure
as describe. Figure 3A demonstrates the age-associated increase in expression of soluble
oligomer proteins in mouse brain using dot bot analysis. Consistent with the hypothesis that
CHIP-/- mice undergo accelerated aging, brain extracts from CHIP-/- mouse express more
abundant soluble oligomer proteins compared to the brain extract from age-matched wild
type mice. Figure 3B demonstrates the dot blot result from a positive (a purified protein of
mutant α-B-crystallin, R120G) and negative (a purified protein of wild-type α-B-crystallin)
control for anti-oligomer antibody.
2-2-2. Measuring 26S proteasome activity using fluorogenic substrates—The
ubiquitin proteasome system (UPS) represents one of the major proteolytic systems used by
cells to degrade damaged or worn cytosolic, endoplasmic reticulum, and nuclear proteins via
the 26S proteasome. UPS dysfunction has been linked to the pathogenesis of several
neurodegenerative diseases as well as the aging process [1,42-44]. In addition, 26S
proteasome activity can be compromised by several conditions such as an overload of
substrates including misfolded proteins and aggregates [45]. Other circumstance such as
energy deficit, decreased expression of proteasome subunits, and stress condition are also
known to contribute to defects in 26S proteasome activity [7,46]. The 26S proteasome
consist of a central catalytic core complex called the 20S unit and two 19S regulatory units
[47,48]. The 20S catalytic core complex also contains six peptidase sites: two chymotrypsin-
like, two caspase-like and two trypsin-like sites. Although the 20S core itself can exist as a
free form unit (which is actually more stable than the 26S complex), studies suggest that
only the 26S proteasome plays a critical role in protein degradation since the 20S
proteasome is not able to degrade intracellular proteins or polyubiquitinated proteins under
physiological conditions. Proteolysis via the 26S proteasome is an ATP dependent process,
which is another distinguishing feature that sets it apart from the 20S proteasome [49]. The
specific activity of each peptidase within the 26S proteasome can be determined in tissue
lysates using a fluorophore (7-amino-4-methylcoumarin, AMC)-conjugated specific peptide
substrate and the kinetic assay described below [50]. Since all three peptidase activities
reflect 26S proteasome function, the activity of all sites needs to be monitored to evaluate
the capacity of proteasome. It bears noting that this assay involves using fluorogenic peptide
substrates that consist of few peptides, and hence are considerably less complex than the
native protein entities with which the 26S proteasome would usually deal. As such, even
when there are no detectable defects in this assay there may still be other defects that go
unnoticed that would be noticeable had the substrate been more complex in nature (for
example entire ubiquitinated proteins that need to be unfolded before proteolysis can occur).
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Nonetheless, measuring peptidase activity in this way is useful for determining 26S
proteasome activity as long as the limitations of this assay are kept in mind when
interpreting data.
2-2-2-1 Preparation of tissue lysates for 26S proteasome assay: To prepare crude tissue
lysates for a proteasome activity assay, tissues (a minimum of 50 to 100 mg of tissues) are
homogenized in a lysis buffer (250 mM sucrose, 50 mM Tris, pH 7.5, 5 mM MgCl2, 0.5
mM EDTA, 1 mM dithiothreitol) to which 5mM ATP and 0.025% Digitonin are added
immediately before use. The addition of ATP is necessary in order to distinguish 26S
proteasome activity from 20S proteasome. Tissue homogenates are incubated in 4°C for 10
min for maximum lysis by digitonin and are then centrifuged (15000g, 15min at 4°C) to
obtain soluble tissue lysates for the assay. Protein concentration is measured by the BCA
method and tissue lysates are stored at -80°C until needed for assay analysis. To avoid
alteration in proteasome activity by frequent freezing and thawing cycles, tissue lysates
should be aliquoted into several tubes.
2-2-2-2 Kinetics assay for peptidase activities in tissue lysates: To measure the activity of
each peptidase in the 26S proteasome, 20 to 30 ug of tissue protein extract (in the case of
skeletal muscle and liver) are added to the proteasome reaction buffer (50 mM Tris, pH 7.5,
40 mM KCl, 1 mM MgCl2, 1 mM dithiothreitol, 0.5 mM ATP, and 0.05 mg/ml bovine
serum albumin) to which DTT, ATP, and albumin are added immediately before the start of
the assay. Appropriate protein amounts need to be determined for each different tissue
studied due to the variation in proteasome activity between tissues. Fluorogenic substrates
purchased from Biomol (75μM of Suc-LLVY-AMC for Chymotrypsin-like activiy; 150μM
of Boc-LRR-AMC for Trypsin-like activiy; 75μM of Ac-nLPnLD-AMC for Caspase-like
activity) are diluted in the proteasome reaction buffer and pre-warmed at 37°C for 10 min
before adding to tissue lysates. Fluorescence is measured every 2 min at 37°C for 80
minutes using a Wallace Victor2 Spectrofluorometer (the excitation wavelength is 355 nm,
and the emission wavelength is 460 nm). To remove nonspecific substrate hydrolysis,
another set of proteins is pre-incubated with the proteasome inhibitor epoxomycin (20 μM
final concentration, Biomol) for 30 min at 37°C before adding the fluorogenic substrates and
fluorescence units are subtracted from each measurement. Linear regression (GraphPad
Prizm 4) is calculated by fluorescence unit (AFU/ug protein) and time (min) and the slope
(AFU/min) of linear regression analysis is used for the comparison of peptidase activity.
Each sample is assayed in triplicate and the average of triplicate measurement is used for
linear regression analysis. Only slopes with good linearity (R2 > 0.95) are used and the data
from at least 3 different mice are subjected to statistical analysis (student t-test). This assay
uses results obtained by continuous assay based on linearity as opposed to data obtained
from an endpoint analysis. Endpoint analysis obtains data from one time point. This form of
analysis is simple and often used in these types of assays. However, endpoint analysis
allows the possibility of detecting saturated and inaccurate activity due to limited substrate
availability in the reaction. In addition, in this particular assay, 26S proteasome subunits and
activity can vary between samples even if they are at the same protein concentration [46].
Measuring peptidase activity via a continuous assay by calculating linear regression affords
the ability to detect activity throughout the assay. As such, it allows the opportunity to
exclude time points where saturated activities are obvious due to the exhaustion of substrates
or higher 26S proteasome activity in certain samples, making the analysis of the data
significantly more accurate. Figure 4A indicates representative kinetics assay from our
previous studies using skeletal muscle analyzed for chymotrysin-like, trypsin-like and
caspase-like activites. Figure 4B indicates reduced chymotrypsin-like activity in liver tissue
from CHIP-/- mouse at 12-month old compared to that from age-matched CHIP+/+ mouse.
Using this assay we demonstrated decreases in 26S proteasome activity in CHIP-/- mouse
associated with their premature aging phenotype (Fig 4B).
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There is a growing body of evidence suggesting that maintenance of protein homeostasis is a
key regulatory mechanism in determining the speed of the aging process as well as the
development of diseases linked to proteotoxicity such as neurodegenerative diseases [4,8].
Proteotoxicity is mediated by the accumulation of either toxic disease-specific proteins (for
example Aβ protein in AD and huntingtin in Huntington's disease) or a broader range of
misfolded/altered protein species (for example in the aging process). In addition, impairment
of protein degradation systems such as the UPS and autophagy system contribute to the
induction of proteotoxicity during the aging process as well as neurodegenerative diseases
[1,7]. In this Methods review, we have presented a diverse range of techniques that we used
in our study of the evaluation of the aging phenotype in a mouse model of protein
dyshomeostasis [12]. Most of the techniques we cover (including measurement of soluble
oligomer production, proteasomal activity, oxidative assays and proliferation assays) can
also be attributed to studies involving the progression of neurodegenerative diseases.
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Figure 1. Kaplan-Meier survival curve
A Kaplan-Meier survival analysis in a cohort of female CHIP+/+ (n=24) and CHIP-/- mice
(n=27). CHIP-/- mice have a significantly shortened lifespan compared with CHIP+/+ mice
(Logrank test, p=0.0003).
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Figure 2. Dermal thickness analysis and SA-β-gal activity as a measure of aging
A. Representative histological sections of skin from CHIP-/- and CHIP+/+ mice at 12 month
of age (original magnification 200×). CHIP-/- mice show a greatly reduced dermis layer in
the skin compared with CHIP+/+ mice. The black bar indicates the dermis layer within the
skin section. (Dermis; d, Subcutaneous fat; f, Muscle; m) B. Representative images of SA-β-
gal staining in CHIP-/- and CHIP+/+ MEFs at P8 (original magnification 200×). Blue
staining in the cells indicates SA-β-gal activity. Figure 2 is modified from Min JN et al.,
Mol. Cell. Biol., 2008.
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Figure 3. Dot blot analysis for oligomer protein in brain tissues
A. Expression of misfolded oligomer proteins in brain tissues (10ug of protein) obtained
from indicated genotype and age groups as measured by a dot-blot analysis using the anti-
oligomer (A11) antibody. Actin was used as a loading control. B. Dot blot analysis showing
positive (+) and negative (-) controls for the anti-oligomer antibody (see text). Figure 3 is
modified from Min JN et al., Mol. Cell. Biol., 2008. Since the A11 antibody is directed
against a common oligomeric conformation, identification of the specific oligomerized
protein(s) in this assay is not possible.
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Figure 4. 26S proteasome activity assay
A. Representative graphs and linear regressions for proteasome assays using three different
fluorogenic substrates. B. Left panel; Graph for chymotrypsin-like activity in a liver sample
from CHIP+/+ and CHIP-/- mice at 12 months of age. Data from each mouse sample (n=3
per genotype) are shown in graph and individual line generated from linear regression
analyses from each data set. Right panel; Percentile of chymotrypsin-like activity (slopes
from the graph on the left) was measured relative to the activity (slopes) in CHIP+/+ mice.
Data shown were obtained from left graph and indicated by mean ± SEM. *, p<0.05
(Student's t- test). Figure 4B. is modified from Min JN et al., Mol. Cell. Biol., 2008.
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